Pindolol
Pindolol
Definition
An aryloxypropanolamine derivative with antihypertensive property. Pindolol competitively binds to beta-adrenergic receptors, resulting in a decrease in beta-adrenergic activities, i.e., vasodilation, and negative chronotropic and inotropic effects. In addition, this agent blocks serotonin (5-HT) 1A receptors, thereby increasing the available serotonin in the brain. Increased serotonin levels augment the antidepressant action of selective serotonin reuptake inhibitors and monoamine oxidase inhibitors.
Also known as 1-(1H-Indol-4-yloxy)-3-((1-methylethyl)amino)-2-propanol, Carvisken, PINDOLOL, Visken — per NCIT
Also identified as
- ATC C07AA03 per RXNORM
- NCIT NCIT:C47673 per NCIT
- SCTID 18381001 per RXNORM
- SCTID 387102009 per RXNORM
- UNII BJ4HF6IU1D per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Hypertensive disorder | may treat | MEDRT · Public domain (U.S. Government work) |
| Myocardial infarction | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Cardiovascular system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Heart | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Musculature | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Musculoskeletal system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Myocardium | may treat a disease of this organ | DERIVED · CC BY 4.0 |
5 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.